InMed Pharmaceuticals Inc.
INM | NASDAQ
$1.44
+$0.08 (+5.88%)
Sep 21, 2026, 11:20 AM ET · Market open
Fiscal Year Period Ending | FY 2026 Jun 29, 2026 | FY 2025 Jun 29, 2025 | FY 2024 Jun 29, 2024 | FY 2023 Jun 29, 2023 | FY 2022 Jun 29, 2022 | FY 2021 Jun 29, 2021 |
|---|---|---|---|---|---|---|
Revenue | 3.18B | 4.94M | 4.6M | 4.14M | 1.09M | n/a |
Cost of Revenue | 2.47B | 3.24M | 3.5M | 2.73M | 545.89K | n/a |
Gross Profit | 709.84M | 1.71M | 1.1M | 1.4M | 543.55K | n/a |
Operating Income | -1.19B | -7.92M | -8.13M | -8.38M | -13.79M | -12.17M |
Interest Income | n/a | 156.54K | 721.97K | 652.37K | 123.72K | 16.02K |
Pretax Income | -1.19B | -8.16M | -7.67M | -7.93M | -18.6M | -12.65M |
Net Income | -1.19B | -8.16M | -7.68M | -7.95M | -18.6M | -12.65M |
Selling & General & Admin | 1.88B | 6.56M | 5.8M | 5.85M | 6.87M | 5.55M |
Research & Development | 15.13M | 2.85M | 3.22M | 3.73M | 7.28M | 6.62M |
Other Expenses | 2.2M | 212.84K | 219.6K | 202.25K | 185.66K | n/a |
Operating Expenses | 1.9B | 9.62M | 9.24M | 9.78M | 14.34M | 12.17M |
Interest Expense | n/a | 373.11K | n/a | n/a | n/a | 360.35K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 4.36B | 12.86M | 12.73M | 12.51M | 14.88M | 12.17M |
Income Tax Expense | n/a | n/a | 7.1K | 13.1K | n/a | n/a |
Shares Outstanding (Basic) | n/a | 975.99K | 381.05K | 122.42K | 1.12K | 13.44K |
Shares Outstanding (Diluted) | n/a | 975.99K | 381.05K | 122.42K | 1.12K | 13.44K |
EPS (Basic) | n/a | -8.36 | -20.14 | -64.92 | -16.58K | -938.91 |
EPS (Diluted) | n/a | -8.36 | -20.14 | -64.92 | -16.58K | -938.91 |
EBITDA | -1.19B | -7.26M | -7.06M | -7.34M | -18.09M | -12.17M |
EBIT | n/a | -7.79M | -7.67M | -7.93M | -18.6M | -12.32M |
Depreciation & Amortization | 2.2M | 534.73K | 604.52K | 596K | 511.79K | 149.84K |
Add to Watchlist
Select watchlists to add or remove INM